Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.44 |
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455844 | 0.90 | SLC6A5 (0.46) | NR1H2ALOX5APPPARDSLC6A5PTPN7 | |
| SCHEMBL5455811 | 0.89 | RXRA (0.46) | NR1H2RXRANR1H3ALOX5APPPARD | |
| SCHEMBL5455835 | 0.83 | NR4A2 (0.48) | RXRAPPARDSLC6A5 | |
| SCHEMBL5442874 | 0.79 | PPARD (0.50) | ALOX5APPPARDPPARGPTPN7 | |
| SCHEMBL5451042 | 0.78 | GRIK1 (0.44) | KDM4ETDP1 | |
| SCHEMBL5442953 | 0.75 | PPARG (0.49) | PPARG | |
| SCHEMBL5464776 | 0.75 | CYP11B1 (0.41) | NR1H2RXRANR1H3PPARGPTPN7 | |
| SCHEMBL5446217 | 0.74 | ESR1 (0.46) | CYP3A4PPARG | |
| SCHEMBL5447426 | 0.74 | PGR (0.39) | ALOX5APPPARDPPARG | |
| SCHEMBL5448677 | 0.73 | PPARG (0.61) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123495-A1 | PYRROLO-NAPHTHYL ACIDS AND METHODS FOR USING THEM | WYETH (US) | 2007-05-31 | — | — | US | disclosed |
| EP-1781641-A1 | PYRROLO-NAPHTHYL ACIDS AS PAI-1 INHIBITORS | Wyeth (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7186749-B2 | Pyrrolo-naphthyl acids and methods for using them | WYETH (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060052349-A1 | Pyrrolo-naphthyl acids and methods for using them | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023864-A1 | PYRROLO-NAPHTHYL ACIDS AS PAI-1 INHIBITORS | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123495-A1 | PYRROLO-NAPHTHYL ACIDS AND METHODS FOR USING THEM | SERPINE1, SERPINC1, SERPINB1 | NR1H2 1166/4885RXRA 520/4885NR1H3 1029/4885 |
| US-20060052349-A1 | Pyrrolo-naphthyl acids and methods for using them | SERPINE1, SERPINC1, SERPINB1 | NR1H2 1166/4885RXRA 520/4885NR1H3 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.